| ID | 1222 |
| Name of the vaccine | Gynevac |
| Microbe | Bacteria |
| Disease name | Bacterial Vaginosis |
| Name of bacteria | Gardnerella vaginalis, Lactobacillus, Prevotella, Mobiluncus, Bacteroides, Pepto streptococcus, Fusobacterium, Veillonella, Eubacterium, Mycoplasma hominis, Ureaplasma urealyticum, Streptococcus viridans and Atopobium vaginae. |
| Type of vaccine | Inactivated |
| Nucleic acid content | Circular DNA |
| Age | 18 to 55 years (Females) |
| Description of the vaccine | Lactobacillus strains 15, 34, 79, 84, 127. |
| Name of the manufacturer | Amvac Kft. |
| Name of the manufacturing country | Hungary |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic bacteria (increase in number). |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single injection per week, for 4 weeks. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02173184 |
| Reference | https://emedicine.medscape.com/article/254342-overview |
| Other name | NA |
| Additional Links | https://www.ncbi.nlm.nih.gov/nuccore/AP012332
|